Safety of Risankizumab during Pregnancy in IBD
Lay Summary Our real-world data show that treatment with risankizumab in women with IBD does not confer additional risk for adverse obstetric or neonatal outcomes relative to anti-TNF or conventional therapies.
Authors
- Yulia Ron (ORCID: https://orcid.org/0009-0005-3783-5284)
- Ami Ben Yaʼacov (ORCID: https://orcid.org/0000-0001-7820-8299)
- Hilla Reiss Mintz
- Tali Mishael
- Noa Tsur
- Bella Ungar
- Benjamin Koslowsky (ORCID: https://orcid.org/0000-0002-6935-6051)
- Ariella Bar Gil Shitrit
- Irit Avni-Biron
Institutions
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Sheba Medical Center (IL)
- Rabin Medical Center (IL)
- Shaare Zedek Medical Center (IL)
- Mayanei Hayeshua Medical Center (IL)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1093/ibd/izaf305
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00